Genworth Financial Inc Common Stock vs 22nd Century Group Inc — how do they compare? Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.36B), while 22nd Century Group Inc trades at $0.65 (market cap $475.95K). The key difference: Genworth Financial Inc Common Stock is far larger — about 7059.6× 22nd Century Group Inc's market cap, and Genworth Financial Inc Common Stock is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and 22nd Century Group Inc for 33 Days on average.
| GNW | XXII | |
|---|---|---|
Market Cap | $3.36B | $475.95K |
Volume | 3,333,156 | 78,911 |
Sector | Financials | Consumer Staples |
52-Week High | $10.60 | $483.00 |
52-Week Low | $7.94 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $2.87B | -$3.83M |
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →